Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
- WuXi Biologics has aligned its ESG strategy with the United Nations Sustainable Development Goals (SDGs), as well as with its stakeholders'...
Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9...
WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, has been recognized as the Industry Top-Rated Company in 2022 by...
WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, today announced that the company has won the 2022 CMO Leadership Awards in all ...
We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries in Shanghai and Wuxi will be...
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed a...
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and ImmuneOncia Therapeutics, Inc.,...
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has successfully...
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced it has successfully...
WuXi Biologics (WuXi Bio) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has received...
Revenue Increases by 126.7% Y-o-Y to RMB4,406.8 Million Gross Profit Grows by 191.7% Y-o-Y to RMB2,296.8 Million Adjusted Net Profit Attributable to...
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after...
WuXi Biologics ("WuXi Bio") (2269.HK), ein weltweit tätiges Unternehmen mit führenden Open-Access-Biologics-Technologieplattformen, gab bekannt, dass ...
WuXi Biologics (« WuXi Bio ») (2269.HK), une société mondiale possédant des plates-formes technologiques de pointe en matière de produits biologiques ...
WuXi Biologics ("WuXi Bio") (2269.HK), compañía global con plataformas líderes de tecnología biológica de acceso abierto, anunció que ha recibido la...
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has received the...
WuXi XDC ("XDC"), a global CDMO company dedicated to end-to-end bioconjugates services, and LegoChem Biosciences (141080KS, "LCB"), today announced...
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held,...
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and WuXi STA, a subsidiary of WuXi...
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has been...
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has...
Revenue Increased by 40.9% Y-o-Y to RMB5,612 Million Gross Profit Rose by 52.7% Y-o-Y to RMB2,533 Million Net Profit Grew by 67.5% Y-o-Y to RMB1,693...
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced it has entered into...
WuXi Vaccines, une organisation de développement et de fabrication sous contrat (CDMO) de vaccins de premier plan au niveau mondial, a annoncé...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.